ATI RN
ATI Pathophysiology Exam 1
1. What causes type I diabetes?
- A. Overproduction of insulin from the beta cells of the pancreas
- B. Destruction of the beta cells within the pancreas, resulting in an inability to produce insulin
- C. Loss of insulin receptors on the target cells, resulting in insulin resistance
- D. A pituitary tumor in the brain, resulting in increased antidiuretic hormone production
Correct answer: B
Rationale: Type I diabetes is caused by the destruction of the beta cells in the pancreas, leading to an inability to produce insulin. This results in a lack of insulin, leading to hyperglycemia. Choice A is incorrect as type I diabetes is characterized by a deficiency of insulin production, not overproduction. Choice C describes the pathophysiology of type 2 diabetes, where insulin receptors become less responsive to insulin. Choice D is unrelated to type I diabetes as it describes a pituitary tumor causing increased antidiuretic hormone production.
2. A patient is prescribed raloxifene (Evista) for osteoporosis. What is the primary mechanism of action for this medication?
- A. Raloxifene decreases bone resorption, which helps to maintain or increase bone density.
- B. Raloxifene increases calcium absorption in the intestines, which helps build stronger bones.
- C. Raloxifene stimulates new bone formation by increasing osteoblast activity.
- D. Raloxifene decreases calcium excretion by the kidneys, helping to maintain bone density.
Correct answer: A
Rationale: Raloxifene decreases bone resorption, which helps to maintain or increase bone density, making it effective in the prevention and treatment of osteoporosis.
3. What is the major effect of filgrastim (Neupogen) in a patient with chronic renal failure?
- A. Decreases neutropenia related to chemotherapy
- B. Decreases white blood cells related to infection
- C. Decreases growth of blood vessels due to ischemia
- D. Decreases platelet count related to bleeding
Correct answer: A
Rationale: The major effect of filgrastim (Neupogen) is to stimulate the production of neutrophils, thereby decreasing neutropenia in patients undergoing chemotherapy. This medication helps the bone marrow produce more white blood cells, specifically neutrophils, to reduce the risk of infections associated with low neutrophil counts. Choices B, C, and D are incorrect because filgrastim does not decrease white blood cells related to infection, growth of blood vessels, or platelet count related to bleeding.
4. What is the distinguishing feature of Hodgkin disease noted on histologic exam?
- A. Reed-Sternberg cells
- B. Red-stained cells
- C. Human Papillomavirus
- D. B-cells and T-cells
Correct answer: A
Rationale: The correct answer is A: Reed-Sternberg cells. Reed-Sternberg cells are large, abnormal B-cells that are characteristic of Hodgkin's lymphoma. These cells are identified on histologic examination of lymph node biopsies from patients with Hodgkin disease. Choice B, 'Red-stained cells,' is vague and does not describe a specific feature of Hodgkin disease. Choice C, 'Human Papillomavirus,' is incorrect as Hodgkin disease is not caused by HPV. Choice D, 'B-cells and T-cells,' is incorrect as Hodgkin disease is characterized by the presence of Reed-Sternberg cells, which are abnormal B-cells.
5. Which of the following is found in higher concentrations within intracellular fluid?
- A. Magnesium
- B. Sodium
- C. Chloride
- D. Bicarbonate
Correct answer: A
Rationale: Magnesium is the correct answer as it is found in higher concentrations within intracellular fluid, where it plays vital roles in various cellular functions. Sodium, chloride, and bicarbonate are predominantly found in extracellular fluid rather than intracellular fluid, making them incorrect choices for this question.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access